A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma
NCT05840289
·
clinicaltrials.gov ↗
UNKNOWN
Status
94
Enrollment
OTHER
Sponsor class
Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma
Interventions
OTHER:
fractionated first dose rituximab
Sponsor
University Hospital, Geneva